✦ LIBER ✦

A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/Progressive or advanced solid tumors of childhood : A report from the Australia and New Zealand Children's Cancer Study Group

✍ Scribed by Paul A. Carpenter; Les White; Geoffrey B. McCowage; Vimala Nayanar; Ian Toogood; Peter J. Shaw; Lianne Lockwood; Karen Tiedemann; for the Australia; New Zealand Children's Cancer Study Group

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 130 KB
Volume: 80
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19970801)80:3<489::aid-cncr17>3.0.co;2-t

No coin nor oath required. For personal study only.

✦ Synopsis

promising salvage regimen. Continued accrual of patients and increased duration of follow-up has resulted in substantial experience with VETOPEC.

📜 SIMILAR VOLUMES

Granulocyte-macrophage colony-stimulatin

Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: A report from the Australia and New Zealand Children's Cancer Study Group

✍ McCowage, Geoffrey B.; White, Les; Carpenter, Paul; Lockwood, Lianne; Toogood, I 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

## Purpose: Combination chemotherapy with vincristine, etoposide, and high-dose, escalating cyclophosphamide (vetopec) is an effective regimen in pediatric patients with high-risk solid tumors. the toxicity of the regimen is predominantly haematologic. this study addressed the role of recombinant h

A Phase I study of granulocyte-macrophag

A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors : A report of the Children's Cancer Group

✍ Mitchell S. Cairo; Mark D. Krailo; Joel A. Weinthal; Rita Secola; Sharon Bergero 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

## Background: This phase i trial was developed to determine the safety, biologic activity, and effects on hematopoietic recovery of pixy321 following ifosfamide, carboplatin, and etoposide chemotherapy for children with recurrent or refractory solid tumors. ## Methods: Children (age < 22 years a